Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase II, Double-Blind, Vehicle Controlled Study to Determine the Efficacy, Safety and Toleration of SRD441 Ointment in Patients With Atopic Dermatitis
Atopic Dermatitis is a chronic inflammatory skin disease that affect 10 to 15% of children and 2 to 10% of adults. AD is characterised by an itchy skin eruption and may cover large parts of the body. The exact cause is unknown but is thought to be an interplay between genetic and and environmental factors. The objective of this study is to determine whether SRD441 ointment is a safe and effective therapy for mild to moderate Atopic Dermatitis.
A phase II, double-blind, vehicle controlled study to determine the efficacy, safety and toleration of SRD441 ointment in patients with atopic dermatitis -
A phase II, double-blind, vehicle controlled study to determine the efficacy, safety and toleration of SRD441 ointment in patients with atopic dermatitis -
100 Clinical Results associated with Serentis, Inc.
0 Patents (Medical) associated with Serentis, Inc.
100 Deals associated with Serentis, Inc.
100 Translational Medicine associated with Serentis, Inc.